Antisense anti-IGF-I therapy of primary hepatic cancer

Trojan, L.; A, Ly; Upegui-Gonzalez, Lia C.; Jarocki, P.; Shevelev, Alexander; Sierżęga, Marek; Wei, Ming; Lafarge‐Frayssinet, C.; Kopiński, Piotr; Pan, Ya-min; Kulig, Jan; Anthony, Donald D.; Popiela, T; Duc, Huynh Thien; Trojan, Jerzy

doi:10.1007/s12558-008-0005-9

Cited by 6 publications

(16 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PBL cells have shown an increase in CD8 + CD28 + molecules with a characteristic switching from CD8 + 11b + to CD8 + 11b − phenotype, observed after two cell vaccinations, reflecting the enhanced activation of cytotoxic T-cells in blood. These results concerning the switching CD8 + 11b + to CD8 + 11b − in different treated tumours have confirmed previously obtained data in glioblastoma and hepatoma treatment using antisens anti-IGF-I approach [4, 28]. The work in progress has also shown, in different treated tumours described here, an increased percentage of T CD25 (interleukin-2 receptor), in the context of CD4, which has confirmed the results obtained in glioblastoma treatment [4].…”

Section: Discussionsupporting

confidence: 91%

Methodology for Anti-Gene Anti-IGF-I Therapy of Malignant Tumours

Trojan

Pan

Wei

et al. 2012

Chemotherapy Research and Practice

View full text Add to dashboard Cite

The aim of this study was to establish the criteria for methodology of cellular “anti-IGF-I” therapy of malignant tumours and particularly for glioblastoma multiforme. The treatment of primary glioblastoma patients using surgery, radiotherapy, and chemotherapy was followed by subcutaneous injection of autologous cancer cells transfected by IGF-I antisense/triple helix expression vectors. The prepared cell “vaccines” should it be in the case of glioblastomas or other tumours, have shown a change of phenotype, the absence of IGF-I protein, and expression of MHC-I and B7. The peripheral blood lymphocytes, PBL cells, removed after each of two successive vaccinations, have demonstrated for all the types of tumour tested an increasing level of CD8+and CD8+28+molecules and a switch from CD8+11b+to CD8+11. All cancer patients were supervised for up to 19 months, the period corresponding to minimum survival of glioblastoma patients. The obtained results have permitted to specify the common criteria for “anti-IGF-I” strategy: characteristics sine qua non of injected “vaccines” (cloned cells IGF-I(−) and MHC-I(+)) and of PBL cells (CD8+increased level).

show abstract

Section: Discussionsupporting

confidence: 91%

Methodology for Anti-Gene Anti-IGF-I Therapy of Malignant Tumours

Trojan

Pan

Wei

et al. 2012

Chemotherapy Research and Practice

View full text Add to dashboard Cite

show abstract

“…Using cancer immunogene therapy of anti-gene anti IGF-I approach, the median survival of treated glioblastoma patients has reached 22-24 months. But the near future in treating this group of disorders belongs to a combination of treatment: classical surgery, radiotherapy with immunotherapy, pharmacologic therapy, growth factor inhibitors, and the use of the antisense/triple helix gene blockade approach targeting signal transduction pathway elements of cancer processes [16,22,23,36,66,90,125,[138][139][140][141][142][143][144][145][146][147].…”

Section: Resultsmentioning

confidence: 99%

Oncoproteins Targeting: Antibodies, Antisense, Triple-helix. Case of Anti IGF-I Cancer Immunogene Therapy

Trojan¹

2019

Antisense Therapy

View full text Add to dashboard Cite

AFP and IGF-I oncoproteins were introduced as biomarkers for cancer diagnosis and targeted in cancer therapy on protein level, but also on transcription and translation levels. The protein level was targeted using an injection of antibodies or radiolabeled proteins. The transcription and translation levels were targeted by triple helix and antisense technologies, respectively. AFP was especially useful for diagnosis and therapy of liver cancer, IGF-I was applied in diagnosis and therapy of colon, prostate, liver, uterus, ovary and brain tumors. The most spectacular results were obtained with IGF-I anti-gene strategy. IGF-I antisense (AS)/triple helix (TH) gene therapy was successfully introduced in clinical trial in the USA and Europe. When using IGF-I anti-gene therapy, cancer cells provided from biopsies were transfected in vitro with IGF-I AS, IGF-I TH expression vectors. A decrease in IGF-I gene expression of 80 and 60% was demonstrated when using TH and AS technologies, respectively. These transfected cells expressing MHC-I molecules, while injected in vivo, induced immune antitumor response mediated by CD8 lymphocytes. The median survival of treated glioblastoma patients was 21-22 months. IGF-I AS/TH immunogene therapy constitutes one of the most promising approaches in cancer therapy, and more specifically when it comes to glioblastoma treatment.

show abstract

“…The final result of this signal transduction pathway element inhibition is an immune response mediated in vivo by lymphocytes T CD8 and APC cells ( Figure 5). But the near future in treating this group of disorders belongs to a combination of treatment [4,42,70,79,115,130,[144][145][146][147][148][149][150]: classical surgery; radiotherapy with immunotherapy, including the use of dendritic cells pharmacologic therapy; growth factor inhibitors; and the use of the antisense/triple helix gene blockade approach targeting signal transduction pathway elements of cancer processes.…”

Section: Discussionmentioning

confidence: 99%

Neoplastic Brain, Glioblastoma, and Immunotherapy

Trojan¹,

Kasprzak²,

Gutiérrez³

et al. 2020

Brain and Spinal Tumors - Primary and Secondary

View full text Add to dashboard Cite

IGF-I, insulin-like growth factor 1, is present in normal fetal/neonatal brain development and reappears in the mature brain participating in the development of malignant tumor, glioblastoma multiforme. Targeting the IGF-I system has emerged as a useful method to reduce glial malignant development. Downregulation in the expression of IGF-I using antigene anti-IGF-I technology (antisense, AS, and triple helix, TH) applied in glioma cell culture established from glioblastoma biopsies induces the expression of B7 and MHC-I antigens in transfected cells (immunogenicity). The transfected cancer cells, "vaccines," after subcutaneous injection, initiated an immune response mediated by T CD8+ lymphocytes, followed by tumor regression (immunotherapy). The median survival of patients treated by surgery followed by radiotherapy and immunotherapy was 21-24 months. On the other side, the experimental work has demonstrated that IGF-I AS or TH transfected tumor cells fused with activated dendritic cells, DC, showing more striking immunogenic character. Using IGF-I TH/DC "vaccination," the efficiency in suppressing rat glioma tumors is not only relatively higher than that obtained using IGF-I TH cells but is also more rapid.

show abstract

Antisense anti-IGF-I therapy of primary hepatic cancer

Cited by 6 publications

References 27 publications

Methodology for Anti-Gene Anti-IGF-I Therapy of Malignant Tumours

Methodology for Anti-Gene Anti-IGF-I Therapy of Malignant Tumours

Oncoproteins Targeting: Antibodies, Antisense, Triple-helix. Case of Anti IGF-I Cancer Immunogene Therapy

Neoplastic Brain, Glioblastoma, and Immunotherapy

Contact Info

Product

Resources

About